Optieum Biotechnologies Inc.

Optieum Biotechnologies Inc. is at the forefront of biotechnology research, revolutionizing immunity and optimizing CAR-T for breakthrough therapies. Optieum Biotechnologies Inc. is dedicated to driving the evolution of next-generation CAR-T cell therapy through precision-engineered CAR constructs. The company's innovative CAR discovery engine focuses on optimizing the binding domain of CAR to enhance immune cell function, ensuring robust therapeutic efficacy.

Based in Toon-shi, Ehime, Optieum Biotechnologies Inc. is pushing the boundaries of solid tumor treatment, powered by next-generation CAR constructs. The company's primary address is 454 Shitsukawa, Toon-shi, Ehime 791-0204, JP, with an additional location at 6-3-7 Minatojima-minamimachi, Kobe-shi, Chuo-ku, Hyogo 650-0047, JP. Optieum Biotechnologies Inc. is committed to advancing the field of biotechnology and creating innovative solutions for challenging medical conditions.

With a focus on biotechnology and the Eumbody System, Optieum Biotechnologies Inc. specializes in scFv, Chimeric Antigen Receptor, and FAPα, contributing significantly to the development of CAR-T therapies. Optieum Biotechnologies Inc. continues to expand its research and development efforts to provide cutting-edge solutions in the biotechnology sector. We invite the manager of Optieum Biotechnologies Inc. to create a customized and exclusive company showcase and product listing on our platform.